XORTX Therapeutics Inc.
XRTX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.78M | 1.93M | 2.29M | 2.32M | 2.41M |
| Depreciation & Amortization | 109.10K | 105.60K | 111.00K | 117.10K | 115.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.42M | 2.54M | 2.79M | 2.62M | 2.84M |
| Operating Income | -2.42M | -2.54M | -2.79M | -2.62M | -2.84M |
| Income Before Tax | -1.94M | -1.88M | -993.10K | -3.31M | -736.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.94 | -1.88 | -0.99 | -3.31 | -0.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.94M | -1.88M | -993.10K | -3.31M | -736.60K |
| EBIT | -2.42M | -2.54M | -2.79M | -2.62M | -2.84M |
| EBITDA | -2.75M | -2.86M | -3.08M | -2.88M | -2.74M |
| EPS Basic | -0.47 | -0.54 | -0.29 | -1.35 | -0.04 |
| Normalized Basic EPS | -0.30 | -0.34 | -0.18 | -0.84 | -0.02 |
| EPS Diluted | -0.48 | -0.54 | -0.30 | -1.35 | -0.04 |
| Normalized Diluted EPS | -0.30 | -0.34 | -0.18 | -0.84 | -0.02 |
| Average Basic Shares Outstanding | 15.66M | 13.70M | 12.82M | 11.51M | 10.24M |
| Average Diluted Shares Outstanding | 15.66M | 13.70M | 12.82M | 11.51M | 10.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |